



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Correction to *Lancet Gastroenterol Hepatol* 2021; 6: 526–27

Din S, Gaya DR, Arnott IDR. COVID-19: colorectal cancer endoscopic surveillance in IBD. *Lancet Gastroenterol Hepatol* 2021; 6: 526–27—In this Correspondence, the fourth and fifth lines of the second paragraph should read “A qFIT of more than 100 ng/mL (equivalent to >20 µg/g) is associated with a Mayo endoscopic subscore of more than 1, suggesting that qFIT can detect active colonic inflammation.² In the UK, a qFIT score greater than 10 µg/g (in symptomatic cohorts) and more than 80 µg/g (bowel cancer screening population)³ is likely to detect colonic inflammation, confounding its use as a risk stratification tool in inflammatory bowel disease surveillance.” This correction has been made online as of Dec 9, 2021.